CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
about
CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control studyCYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.CYP17 and breast cancer: no overall effect, but what about interactions?CYP17 gene polymorphism in relation to breast cancer risk: a case-control studyCYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control studyThe CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Pharmacogenomics and breast cancer.Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology.Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis.Investigation on MDR1 gene polymorphisms and its relationship with breast cancer risk factors in Chinese women.Investigation on XRCC1 genetic polymorphism and its relationship with breast cancer risk factors in Chinese women.Association analysis between MDR1 genetic variant and breast cancer risk factors in Chinese Han population.The influence of genetic polymorphisms in MDR1 gene on breast cancer risk factors in Chinese.Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women.Association between CYP17 T-34C rs743572 and breast cancer risk.Association of the CYP17 MSP AI (T-34C) and CYP19 codon 39 (Trp/Arg) polymorphisms with susceptibility to acne vulgaris.Genetic diversity, inbreeding and cancer.
P2860
Q24810611-0615EEB2-CE50-4179-83EA-B7840C0FBFB7Q24810733-67782D88-11AD-4E9E-96E6-372F9A5A8D9EQ25257341-DA5760BC-ADE8-47FE-A507-E10BBDFC967EQ25257428-9344492B-B915-43DB-9A46-8F5C489B2E69Q33432351-A617F185-ECE2-4FED-A0CF-DDF45276394BQ33675997-2F1C0AA1-B70B-4C34-A145-0696E39424B3Q35610513-DB1EFA95-4E9F-4B3C-8CED-CC30C994A298Q35610515-B1FC83AC-9760-460F-AB61-B4C22EB9DE89Q37665345-AD927536-7815-4B72-BEA9-1BC42A4DADF3Q39487888-D507821C-29CB-4558-B24C-AB11563FF8ACQ45331930-7812A764-6E4D-4433-98EC-F938321B7673Q45333325-D86BCB1C-C7B0-4436-A27F-270BBC070781Q46171175-1CC1EB2B-1A77-48E3-9C50-84F1C1A8A30BQ47685031-0675D8A6-1387-4070-8E36-AFA32B444CADQ49163775-FA4B56C9-2B70-4498-B563-70DE6FDF73CEQ49503519-0B56535E-7921-4F6C-8718-7DA932CE015BQ51145959-EF659DEB-DC51-47A0-9A87-B7E50E5864BC
P2860
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@ast
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@en
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@nl
type
label
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@ast
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@en
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@nl
prefLabel
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@ast
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@en
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@nl
P2093
P2860
P356
P1476
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors
@en
P2093
Elise D Bowman
Helena Furberg
Jo L Freudenheim
John E Vena
Kirsten B Moysich
Peter G Shields
Sabrina Ahmed
Saxon Graham
P2860
P2888
P304
P356
10.1186/BCR570
P407
P577
2003-01-01T00:00:00Z
P5875
P6179
1041445120